~~<i id='96B3CE4C11'><strike id='96B3CE4C11'><tt id='96B3CE4C11'><pre id='96B3CE4C11'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：knowledge 2025-09-30 05:07:33 - browse：7

Michel Pairet -- health business coverage from STAT — Michel Pairet Courtesy Boehringer Ingelheim

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.

There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar.

In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Sarepta Duchenne therapy fails to meet primary endpoint in trial

entertainment

explore

hotspot

explore

focus

hotspot

MikeReddyforSTATWASHINGTON—Democratsunilaterallydrovemajorreformstothehealthinsuranceandthepharmaceu

WSS

The haunting brain science of long Covid

After Sarepta trial failure, Duchenne families brace for more debate

Kidney transplant patients stopped immunosuppressants in trial

What to watch for from Zogenix and Amicus clinical trials

Humans aren't the only ones with an imagination. Rats have it too

Senate panel puts off hardest PBM reforms for another day

hotspot

entertainment

entertainment

Sports medicine is finally prioritizing gender equality

UHS says company favors patients whose insurance pays more

Activists slam private health insurers over coverage restrictions

Coloradans with cystic fibrosis could lose access to Trikafta

Alkermes shareholders re

CDC Director Mandy Cohen on transparency, trust, and health

Moonlake's readout produced a cash windfall. Risks remain

The haunting brain science of long Covid

Medical leaders decry Supreme Court decision on affirmative action

UHS says company favors patients whose insurance pays more

explore

Bill would allow buprenorphine prescription for addiction via telehealth

Will the FTC rein in IQVIA's health data empire?

Biden warns of ‘dark winter’ during final presidental debate

After Sarepta trial failure, Duchenne families brace for more debate

New Alzheimer's drugs heat up race for early detection blood tests

Humans aren't the only ones with an imagination. Rats have it too

hotspot

explore

focus

hotspot